Peptide vaccination directed against IDO1-expressing immune cells elicits CD8⁺ and CD4⁺ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.

ABSTRACT:

Background

The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpreted as counterbalancing IDO1-mediated immunosuppression. Based on this hypothesis, clinical studies employing an IDO1 peptide-based vaccine approach for cancer treatment have been initiated, but there remains a pressing need to further investigate the immunological ramifications of stimulating the anti-IDO1 T-cell response in this manner.

Methods

CT26 colon carcinoma tumors were evaluated for expression of IDO1 protein by western blot analysis, immunofluorescence microscopy and flow cytometry. Mouse IDO1-derived peptides, predict

SUBMITTER: Dey S 

PROVIDER: S-EPMC7373332 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature